Dr. Bahlis on Updated Data From the MAIA Trial in Multiple Myeloma

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Nizar J. Bahlis, MD, associate professor at University of Calgary, Alberta, Canada, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

The MAIA trial evaluated daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) alone in patients with transplant-ineligible multiple myeloma, approximately half of which were over the age of 75.

According to the updated findings, the progression-free survival (PFS) continued to favor DRd. The median PFS with DRd was still not reached with 68% of the patients remaining progression free, says Bahlis. This compared with a median PFS of 33 months in the control arm. The hazard ratio remains the same at 0.5, translating to a 44% reduction in the risk of death with DRd.

Notably, the complete response (CR) rate deepened with DRd with longer-term follow-up. Nearly 50% of patients achieved a CR or better. Additionally, minimal residual disease (MRD) negativity at a sensitivity of 10-5 rose from 24% to 29%. Longer-term follow-up confirmed that 15% of patients experienced sustained MRD negativity at 6 months, adds Bahlis.

PFS2 also favored DRd with a median PFS2 that has yet to be reached versus 46 months in the control arm. No new toxicities or treatment-emergent adverse effects have been reported with longer term follow-up, adds Bahlis. The results for overall survival are eagerly anticipated this year, concludes Bahlis.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD